Thanks to vast expertise derived from centuries of tradition and an openness to new ideas, the Greek pharmaceutical industry is among the country’s most resilient sectors. Founded in 1928 by Costas Kanaroglou, Cana Laboratories has remained a highly respected and important drug manufacturer and distributor in Greece.
Since the Greek government legalized the use of medical cannabis a few years ago, Cana Laboratories CEO Kosta Kanaroglou, the founder’s grandson, has ventured into this sector believing in the untapped potential of the cannabis sativa plant as an effective alternative to established therapies and an innovative solution to treat certain incurable diseases.
“We want to provide the medical community with an opportunity to seriously consider cannabis as part of their patients’ care protocol with single dose products that have high efficacy, safety and quality. To this end, our subsidiary Cannavail SL is active in the research and development of formulations with optimized cannabinoid bioavailability and has secured a Medical Cannabis Cultivation License via our company Canna Innovative Products SL,” Kanaroglou added.
“As a pharmaceutical company, we have entered the newly emerging and highly promising medical cannabis market with the same high-quality standards and strict business ethics that have characterized our company for the past nine decades,” he said.